（文章来源：证券日报） 证券日报网讯 1月12日，南微医学发布公告称，公司2026年第一次临时股东会审议通过《关于2026年度 日常关联交易额度预计的议案》。 ...

江苏新高的律师事务所 关于 南微医学科技股份有限公司 2026 年第一次临时股东会的 见证法律意见书 地址:南京市秦淮区龙蟠中路 419 号人保(南京)金融大厦 A 座 9、10 楼 电话: (025)84715285 传真: (025)84703306 邮编: 210001 江苏新高的律师事务所 2026年第一次临时股东会的见证法律; 江苏新高的律师事务所 关于南微医学科技股份有限公司 2026 年第一次临时股东会的见证法律意见书 苏高律股字[2026]第[0101]号 致:南微医学科技股份有限公司 江苏新高的律师事务所(以下简称"本所")接受南微医学科技股份有限公 司(以下简称"公司")委托,指派陶洪飞、陆佳佩律师(以下简称"本所律师") 出席公司 2026年第一次临时股东会(以下简称"本次股东会"),就本次股东 会的合法性进行见证并出具法律意见书。 本法律意见书依据《中华人民共和国公司法》(以下简称"《公司法》")、 《中华人民共和国证券法》(以下简称"《证券法》")、《上市公司股东会规 则》(以下简称"《规则》")等相关法律、法规和规范性文件以及《南微医学 科技股份有限公司章程》(以下简称"《公司章程 ...

证券代码：688029 证券简称：南微医学 公告编号：2026-001 南微医学科技股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 1 月 12 日 1、 公司在任董事9人，列席9人； 2、董事会秘书龚星亮出席本次会议；其他高管列席本次会议。 （二） 股东会召开的地点：南京江北新区药谷大道 199 号 1 号楼公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 132 | | --- | --- | | 普通股股东人数 | 132 | | 2、出席会议的股东所持有的表决权数量 | 104,285,733 | | 普通股股东所持有表决权数量 | 104,285,733 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 55.8855 | | 例（%） | ...

Core Viewpoint - The article highlights the growth and international expansion of Nanwei Medical, a leading Chinese medical device company specializing in endoscopic diagnosis and treatment, with a focus on innovation and market penetration in both domestic and international markets [1][8]. Group 1: Company Overview - Nanwei Medical, established over 20 years ago, focuses on endoscopic diagnosis and treatment, developing a wide range of innovative products including endoscopic instruments and microwave/radiofrequency ablation devices [1][5]. - The company has achieved significant market access, with its products approved in over 90 countries and regions, and aims for overseas revenue to account for 58% by the first half of 2025 [1][10]. Group 2: Leadership and Strategy - Li Changqing, the Executive President, transitioned from a technical role to management, emphasizing the importance of both scientific and entrepreneurial skills in driving the company's growth [4]. - The company has established a dual-market strategy, focusing on both domestic and international markets, with a particular emphasis on penetrating the U.S. and European markets [9][11]. Group 3: Product Innovation - Nanwei Medical aims to increase the proportion of innovative products to over 30% within the next 3-5 years, currently standing at 10-15% [8]. - The company has developed over 60 types of products in the endoscopic field, showcasing a comprehensive product line that meets various clinical needs [5][6]. Group 4: Financial Performance - For the first three quarters of 2025, Nanwei Medical reported revenues of 2.381 billion yuan, an 18.29% increase year-on-year, with a net profit of 509 million yuan, up 12.90% [8][10]. - The company has shown consistent revenue growth from 1.980 billion yuan in 2022 to an expected 2.755 billion yuan in 2024 [8]. Group 5: International Expansion - The company has made strategic acquisitions to enhance its direct sales channels in Europe, including the purchase of companies in Portugal and Switzerland, and plans to acquire a 51% stake in a Spanish company [11]. - The establishment of a production base in Thailand is aimed at cost reduction and supply chain diversification [12].

南微医学科技股份有限公司 2026 年第一次临时股东会会议资料 证券代码：688029 证券简称：南微医学 南微医学科技股份有限公司 2026 年第一次临时股东会会议资料 | 2026 | 年第一次临时股东会会议须知 3 | | --- | --- | | 2026 | 年第一次临时股东会议程 5 | | 2026 | 年第一次临时股东会议案 6 | | 议案 | 1《关于 2026 年度日常关联交易额度预计的议案》 6 | 2 南微医学科技股份有限公司 2026 年第一次临时股东会会议资料 2026 年 1 月 南微医学科技股份有限公司 2026 年第一次临时股东会会议资料 2026 年第一次临时股东会 目录 南微医学科技股份有限公司 2026 年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证会议 的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人 民共和国证券法》《上市公司股东会规则》以及《南微医学科技股份有限公司章程》 （以下简称"《公司章程》"）《南微医学科技股份有限公司股东会议事规则》等相 关规定，南微医学科技股份有限公司（以下简称 ...

证券日报网讯 1月5日，南微医学在互动平台回答投资者提问时表示，公司经营情况请关注公司后续定 期公告。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the news is that Nanwei Medical has seen a 5% increase in stock price, reaching 85.64 yuan per share, with a total market capitalization of 16.087 billion yuan [1] - Nanwei Medical, established on May 10, 2000, specializes in the research, development, manufacturing, and sales of minimally invasive medical devices, with its main revenue sources being endoscopic consumables (77.80%), other categories (13.17%), tumor intervention (7.28%), visualization (1.00%), and others (0.74%) [1] Group 2 - From the perspective of major fund holdings, one fund under Rongtong has a significant position in Nanwei Medical, with 324,200 shares held, accounting for 3.88% of the fund's net value, making it the seventh-largest holding [2] - The Rongtong Healthcare Industry Mixed A/B Fund (161616) has a total scale of 708 million yuan and has achieved a year-to-date return of 7.26%, ranking 6303 out of 8155 in its category [2] Group 3 - The fund managers of Rongtong Healthcare Industry Mixed A/B are Wan Minyuan and Liu Xiyang, with Wan having a tenure of 9 years and 135 days and a total fund size of 5.957 billion yuan, achieving a best return of 130.09% during his tenure [3] - Liu Xiyang has a tenure of 1 year and 297 days with a fund size of 839 million yuan, with a best return of -7.72% during his tenure [3]

Group 1 - The core investment theme for the pharmaceutical industry in 2025 is the overseas expansion of innovative drugs, which is expected to yield excess returns compared to the broader pharmaceutical sector and the CSI 300 index [2][21] - The innovative drug index has shown a significant increase, outperforming the pharmaceutical biological index by 37.48 percentage points, with a year-to-date increase of 65.99% [21] - Major transactions in the ADC and dual antibody fields are anticipated to continue, while there is a need to avoid repetitive competition in areas like small nucleic acids and focus on unmet clinical needs [3][4] Group 2 - The report emphasizes the importance of overseas markets for both innovative drugs and medical devices, suggesting that companies should seek growth opportunities beyond domestic market saturation [4][5] - The Chinese pharmaceutical industry is gradually becoming a global innovation center, with significant advancements in dual antibodies and ADCs, while also making strides in emerging fields like small nucleic acids and inhalation formulations [5][6] - The report highlights that the overseas authorization revenue has become a crucial funding source for innovative drug development, with a total upfront payment of $4.551 billion in the first three quarters of 2025 [29][32] Group 3 - The medical device sector is experiencing a shift towards overseas expansion, with a focus on high-value consumables and IVD products, as Chinese companies enhance their market share [7][55] - The export growth of high-value consumables is significant, with a recorded increase of 10.75% in the first half of 2025, particularly in the North American and European markets [57][66] - The report notes that the certification and market establishment processes for high-value consumables are long-term investments, requiring compliance with stringent regulations in the EU and the US [60][61] Group 4 - The recovery of financing in the domestic innovative drug sector has been robust, with a total of 324 financing events amounting to $5.51 billion in the first three quarters of 2025, marking a 67.6% increase year-on-year [70][72] - The CXO industry is experiencing varied recovery rhythms across different segments, with some areas like CDMO seeing order growth due to overseas financing recovery [74]

Group 1 - The core point of the news is that Nanwei Medical has experienced a decline in stock price, dropping 1% to 81.83 yuan per share, with a total market value of 15.372 billion yuan and a cumulative drop of 1.89% over three consecutive days [1] - Nanwei Medical, established on May 10, 2000, and listed on July 22, 2019, specializes in the research, manufacturing, and sales of minimally invasive medical devices [1] - The revenue composition of Nanwei Medical includes 77.80% from endoscopic consumables, 13.17% from other categories, 7.28% from tumor intervention, 1.00% from visualization, and 0.74% from other supplementary sources [1] Group 2 - Jin Xin Fund has a significant holding in Nanwei Medical through its Jin Xin Quality Growth Mixed A Fund (018204), which held 2.89% of its net asset value in 2,300 shares, ranking it as the tenth largest holding [2] - The Jin Xin Quality Growth Mixed A Fund has experienced a year-to-date return of 53.63% and a one-year return of 49.89%, with a total fund size of 7.1923 million [2] - The fund manager, Huang Biao, has been in position for 4 years and 222 days, with the best fund return during his tenure being 121.14% [3]

Group 1 - The core point of the news is that Nanwei Medical has experienced a decline in stock price, dropping 1% to 81.83 CNY per share, with a total market capitalization of 15.372 billion CNY and a cumulative decline of 1.89% over three consecutive days [1] - Nanwei Medical, established on May 10, 2000, and listed on July 22, 2019, specializes in the research, manufacturing, and sales of minimally invasive medical devices [1] - The revenue composition of Nanwei Medical is as follows: endoscopic consumables account for 77.80%, other categories 13.17%, tumor intervention 7.28%, visualization 1.00%, and other supplementary items 0.74% [1] Group 2 - From the perspective of fund holdings, Huashang Fund has one fund heavily invested in Nanwei Medical, specifically the Huashang Innovation Medical Mixed A fund, which reduced its holdings by 8,352 shares in the third quarter [2] - The current holding of the Huashang Innovation Medical Mixed A fund is 20,000 shares, representing 3.85% of the fund's net value, ranking as the ninth largest holding [2] - The fund has experienced a year-to-date return of 25.18% and a one-year return of 23.02%, with a total fund size of 31.7429 million CNY [2]